The global market for Endovascular Abdominal Aortic Aneurysm (AAA) was valued at US$3.0 Billion in 2025 and is projected to reach US$4.1 Billion by 2032, growing at a CAGR of 4.7% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Next-generation EVAR systems are emphasizing anatomical adaptability and long-term sealing performance. The development of fenestrated and branched endografts has allowed surgeons to treat aneurysms that were once considered unsuitable for conventional EVAR due to short or angulated necks, or involvement of visceral branches. Innovations such as polymer-based sealing rings, repositionable grafts, and integrated imaging markers are addressing common complications like endoleaks, migration, and access issues. Additionally, the emergence of intraoperative imaging systems, including 3D fusion imaging and robotic-assisted navigation, is streamlining procedural accuracy and reducing contrast and radiation exposure. These technological strides are not only optimizing procedural outcomes but also influencing treatment guidelines and surgeon preferences globally.
In high-risk surgical populations - such as the elderly or those with comorbidities like chronic obstructive pulmonary disease (COPD), renal dysfunction, or coronary artery disease - EVAR offers a viable treatment alternative to traditional open repair. This has driven demand across tertiary hospitals, ambulatory surgical centers, and even hybrid operating rooms tailored for vascular interventions. Furthermore, the growing number of patients requiring reintervention after initial EVAR due to graft degeneration or aneurysm sac enlargement is creating a secondary demand channel for newer, more durable graft technologies. The inclusion of women in AAA risk stratification protocols and the detection of aneurysms through incidental imaging are also contributing to procedural growth, though anatomical differences still pose challenges for universal device applicability.
Asia-Pacific is emerging as a key growth frontier, particularly in Japan, China, and South Korea, where the aging population and urbanization are increasing the incidence of vascular diseases. Japan has been at the forefront in terms of technological adoption, with robust procedural experience and widespread use of custom fenestrated devices. In China, expanding healthcare infrastructure and the development of domestic device manufacturers are enabling rapid market expansion. However, reimbursement disparities and training limitations remain challenges in many emerging economies. In Latin America and parts of the Middle East, adoption is slower but growing, especially in private hospitals catering to higher-income patient segments. Market access strategies such as device leasing, surgical training programs, and hybrid OR installation support are proving effective in these underpenetrated regions.
Regulatory pathways and payer structures are also accelerating growth. With FDA approvals for next-gen devices and CE marks expanding to cover advanced fenestrated and branched solutions, clinical adoption is rising in both traditional and niche anatomical segments. The movement toward value-based healthcare models is aligning well with EVAR's lower complication rates, shorter hospital stays, and reduced postoperative morbidity. Hospitals and surgical centers are investing in hybrid ORs and integrated imaging systems to support these procedures, indicating confidence in the long-term utility of endovascular approaches.
Additionally, industry players are increasingly focused on training and education, launching simulation-based programs and global surgeon networks to standardize procedural expertise. The combination of telehealth for follow-up care and wearable devices for postoperative surveillance is further enriching the treatment ecosystem. Meanwhile, increasing investments in R&D - especially into bioresorbable graft components and AI-enabled imaging tools - suggest that EVAR technology is still in a phase of active evolution. These multifactorial drivers point toward sustained expansion in both procedure volumes and device innovation, firmly establishing EVAR as the dominant modality in AAA management for the foreseeable future.
Global Endovascular Abdominal Aortic Aneurysm (AAA) Market - Key Trends & Drivers Summarized
What Technological Shifts Are Redefining the Treatment Landscape for AAA?
The management of abdominal aortic aneurysms (AAA) has seen a paradigm shift from open surgical repair to minimally invasive techniques, primarily led by endovascular aneurysm repair (EVAR). Technological advancements in stent graft design, catheter delivery systems, and imaging guidance have enabled EVAR to become the dominant intervention method in many high-income healthcare systems. The core of EVAR technology lies in modular stent grafts that can be introduced via femoral artery access and deployed precisely at the aneurysm site, effectively excluding the weakened vessel wall from systemic circulation. The shift toward percutaneous, suture-less access and low-profile devices has significantly expanded the treatable patient population, including those with higher surgical risk.Next-generation EVAR systems are emphasizing anatomical adaptability and long-term sealing performance. The development of fenestrated and branched endografts has allowed surgeons to treat aneurysms that were once considered unsuitable for conventional EVAR due to short or angulated necks, or involvement of visceral branches. Innovations such as polymer-based sealing rings, repositionable grafts, and integrated imaging markers are addressing common complications like endoleaks, migration, and access issues. Additionally, the emergence of intraoperative imaging systems, including 3D fusion imaging and robotic-assisted navigation, is streamlining procedural accuracy and reducing contrast and radiation exposure. These technological strides are not only optimizing procedural outcomes but also influencing treatment guidelines and surgeon preferences globally.
Which Patient Demographics and Risk Profiles Are Driving Clinical Demand?
The burden of abdominal aortic aneurysms is rising, largely influenced by the aging global population and prevalence of modifiable risk factors such as smoking, hypertension, and hyperlipidemia. AAAs are most commonly diagnosed in men aged 65 and older, though incidence among older women is increasingly recognized in epidemiological studies. As a result, screening programs have been introduced in several developed countries targeting at-risk populations, particularly male smokers over the age of 65. The broader implementation of ultrasound-based screening has led to earlier detection of asymptomatic aneurysms, thus expanding the pool of patients eligible for elective EVAR procedures before rupture occurs.In high-risk surgical populations - such as the elderly or those with comorbidities like chronic obstructive pulmonary disease (COPD), renal dysfunction, or coronary artery disease - EVAR offers a viable treatment alternative to traditional open repair. This has driven demand across tertiary hospitals, ambulatory surgical centers, and even hybrid operating rooms tailored for vascular interventions. Furthermore, the growing number of patients requiring reintervention after initial EVAR due to graft degeneration or aneurysm sac enlargement is creating a secondary demand channel for newer, more durable graft technologies. The inclusion of women in AAA risk stratification protocols and the detection of aneurysms through incidental imaging are also contributing to procedural growth, though anatomical differences still pose challenges for universal device applicability.
How Are Regional Ecosystems and Market Access Influencing Uptake?
North America and Western Europe remain the most mature markets for EVAR, driven by high procedural volumes, advanced hospital infrastructure, and favorable reimbursement policies. The U.S. has been a leading adopter of EVAR, supported by the presence of major medical device manufacturers, continuous clinical trials, and a skilled vascular surgery workforce. In the European context, countries like Germany, the UK, and the Netherlands demonstrate strong procedural integration within public health systems, with EVAR accounting for over 70% of elective AAA repairs. Government-funded screening initiatives in these regions further fuel patient identification and referral for endovascular treatment.Asia-Pacific is emerging as a key growth frontier, particularly in Japan, China, and South Korea, where the aging population and urbanization are increasing the incidence of vascular diseases. Japan has been at the forefront in terms of technological adoption, with robust procedural experience and widespread use of custom fenestrated devices. In China, expanding healthcare infrastructure and the development of domestic device manufacturers are enabling rapid market expansion. However, reimbursement disparities and training limitations remain challenges in many emerging economies. In Latin America and parts of the Middle East, adoption is slower but growing, especially in private hospitals catering to higher-income patient segments. Market access strategies such as device leasing, surgical training programs, and hybrid OR installation support are proving effective in these underpenetrated regions.
What Are the Key Forces Powering the Growth of the EVAR Market?
The growth in the endovascular abdominal aortic aneurysm (AAA) market is driven by several factors that collectively shape technology development, procedural adoption, and patient access worldwide. Chief among them is the increasing global prevalence of AAAs, a trend exacerbated by demographic aging, lifestyle-related risk factors, and expanded screening practices. As asymptomatic aneurysms are increasingly detected at an earlier stage, elective EVAR is being prioritized as a safer, less invasive alternative to open surgery. This shift is underpinned by continued innovation in stent graft systems that offer enhanced conformability, sealing capacity, and durability, even in anatomically complex cases.Regulatory pathways and payer structures are also accelerating growth. With FDA approvals for next-gen devices and CE marks expanding to cover advanced fenestrated and branched solutions, clinical adoption is rising in both traditional and niche anatomical segments. The movement toward value-based healthcare models is aligning well with EVAR's lower complication rates, shorter hospital stays, and reduced postoperative morbidity. Hospitals and surgical centers are investing in hybrid ORs and integrated imaging systems to support these procedures, indicating confidence in the long-term utility of endovascular approaches.
Additionally, industry players are increasingly focused on training and education, launching simulation-based programs and global surgeon networks to standardize procedural expertise. The combination of telehealth for follow-up care and wearable devices for postoperative surveillance is further enriching the treatment ecosystem. Meanwhile, increasing investments in R&D - especially into bioresorbable graft components and AI-enabled imaging tools - suggest that EVAR technology is still in a phase of active evolution. These multifactorial drivers point toward sustained expansion in both procedure volumes and device innovation, firmly establishing EVAR as the dominant modality in AAA management for the foreseeable future.
Report Scope
The report analyzes the Endovascular Abdominal Aortic Aneurysm (AAA) market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Product Type (Stent Graft, Synthetic Fabric Graft); End-Use (Hospital End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Stent Graft segment, which is expected to reach US$2.9 Billion by 2032 with a CAGR of a 5.3%. The Synthetic Fabric Graft segment is also set to grow at 3.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $806.9 Million in 2025, and China, forecasted to grow at an impressive 8.2% CAGR to reach $862.1 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Endovascular Abdominal Aortic Aneurysm (AAA) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Endovascular Abdominal Aortic Aneurysm (AAA) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Endovascular Abdominal Aortic Aneurysm (AAA) Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, Artivion Inc., Bentley InnoMed GmbH, Biotronik SE & Co. KG, Boston Scientific Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Endovascular Abdominal Aortic Aneurysm (AAA) market report include:
- Abbott Laboratories
- Artivion Inc.
- Bentley InnoMed GmbH
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Braile Biomedica
- Cardinal Health Inc.
- Cook Medical LLC
- Cordis Corporation
- CryoLife Inc.
- Edwards Lifesciences Corp.
- Endologix LLC
- Getinge AB
- JOTEC GmbH
- LeMaitre Vascular Inc.
- Lifetech Scientific Corp.
- Lombard Medical Ltd.
- Medtronic plc
- MicroPort Scientific Corp.
- Terumo Corporation
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Artivion Inc.
- Bentley InnoMed GmbH
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Braile Biomedica
- Cardinal Health Inc.
- Cook Medical LLC
- Cordis Corporation
- CryoLife Inc.
- Edwards Lifesciences Corp.
- Endologix LLC
- Getinge AB
- JOTEC GmbH
- LeMaitre Vascular Inc.
- Lifetech Scientific Corp.
- Lombard Medical Ltd.
- Medtronic plc
- MicroPort Scientific Corp.
- Terumo Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 275 |
| Published | November 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 3 Billion |
| Forecasted Market Value ( USD | $ 4.1 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
